Clinical Aspects of Bone Metastases in Prostate Cancer

  • Shi-Ming Tu
  • Sue-Hwa Lin
Part of the Cancer Treatment and Research book series (CTAR, volume 118)


Bone is the second most common site of metastases in human cancer. At least two-thirds of the approximately 553,400 Americans who die from cancer each year have bone metastases (Greenlee et al., 2001). Prostate, breast, and lung cancers account for at least 80% of the skeletal metastases. Tumors arising in the prostate and breast are particularly prone to disseminate to bone; up to 85% of patients with these cancers have evidence of bone metastases at autopsy. Carcinomas of the lung, thyroid, and kidney also commonly spread to the bone (30–40%). However, tumors of the gastrointestinal tract rarely metastasize to the bone (5%) (Galasko, 1986).


Prostate Cancer Bone Metastasis Radical Prostatectomy Zoledronic Acid Metastatic Prostate Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Arguello, F., Baggs, R.B., Duerst, R.E., et al. (1990) Pathogenesis of vertebral metastases and epidural spinal cord compression. Cancer, 65, 98–106.PubMedCrossRefGoogle Scholar
  2. Batson, O.V. (1940) The function of the vertebral veins and their role in the spread of metastasis. Annals of Surgery, 112, 138–139.PubMedCrossRefGoogle Scholar
  3. Beer, T.M., Eilers, K.M., Garzotto, M., Egorin, M.J., Lowe, B.A. and Henner, W.D. (2003) Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. Journal of Clinical Oncology, 21, 123–128.PubMedCrossRefGoogle Scholar
  4. Berenson, J.R., Lichtenstein, A., Porter, L., Dimopoulos, M.A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M.J., Blacklock, H.A., Bell, R., Simeone, J., Reitsma, D.J., Heffernan, M., Seaman, J. and Knight, R.D. (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. New England Journal of Medicine, 334, 488–493.PubMedCrossRefGoogle Scholar
  5. Berruti, A., Dogliotti, L., Bitossi, R., Fasolis, G., Gorzegno, G., Bellina, M., Torta, M., Porpiglia, F., Fontana, D. and Angeli, A. (2000) Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. Journal of Urology, 164, 1248–1253.PubMedCrossRefGoogle Scholar
  6. Blitzer, P.H. (1985) Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis. Cancer, 55, 1468–1472.PubMedCrossRefGoogle Scholar
  7. Boyle, B.J., Zhao, X.-Y., Cohen, P. and Feldman, D. (2001) Insulin-like growth factor binding protein-3 mediates 1α, 25-dihydroxyvitamin D3 growth inhibition in the LNCaP prostate cancer cell line through p21/WAFl. Journal of Urology, 165, 1319–1324.PubMedCrossRefGoogle Scholar
  8. Byar, D.P. (1977). VACURG studies on prostate cancer and its treatment. Philadelphia, Lea and Febiger.Google Scholar
  9. Chodak, G.W., Thisted, R.A., Gerber, G.S., Johansson, J.E., Adolfsson, J., Jones, G.W., Chisholm, G.D., Moskovitz, B., Livne, P.M. and Warner, J. (1994) Results of conservative management of clinically localized prostate cancer. New England Journal of Medicine, 330, 242–248.PubMedCrossRefGoogle Scholar
  10. Chott, A., Sun, Z., Morganstern, D., Pan, J., Li, T., Susani, M., Mosberger, I., Upton, M.P., Bubley, G.J. and Balk, S.P. (1999) Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type I insulin-like growth factor receptor. American Journal of Pathology, 155, 1271–1279.PubMedCrossRefGoogle Scholar
  11. Chung, L.W.K. (1993) Implications of stromal-epithelial interaction in human prostate cancer growth, progression and differentiation. Seminars in Cancer Biology, 4, 183–192.PubMedGoogle Scholar
  12. Chung, L. W.K. (1995) The role of stromal-epithelial interaction in normal and malignant growth. Cancer Surveys, 23, 33–42.PubMedGoogle Scholar
  13. Chybowski, F.M., Keller, J.J.L. and Bergstrahl, E.J. (1991) Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. Journal d Urologie, 145, 313–318.Google Scholar
  14. Clarke, N.W., McClure, J. and George, N.J.R. (1992) Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer. British Journal of Urology, 69, 64–70.PubMedCrossRefGoogle Scholar
  15. Coleman, R.E. (1991). Bone metastases: Diagnosis and Treatment. London, Springer-Verlag.Google Scholar
  16. Colvard, D.S., Eriksen, E.F., Keeting, P.E., Wilson, E.M., Lubahn, D.B., French, D.B., Riggs, B.L. Speisberg, T.C. (1989) Identification of androgen receptors in normal human osteoblast-like cells. Proceedings of National Academy of Sciences USA, 86, 854–857.CrossRefGoogle Scholar
  17. Costa, L., Demers, L.M., Gouveia-Oliveira, A., Schaller, J., Costa, E.B., de Moura, M.C. and Lipton, A. (2002) Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. Journal of Clinical Oncology, 20, 850–856.PubMedCrossRefGoogle Scholar
  18. Daniell, H.W. (1997) Osteoporosis after orchiectomy for prostate cancer. Journal of Urology, 157, 439–444.PubMedCrossRefGoogle Scholar
  19. Dehdashti, F., Siegel, B.A., Griffeth, L.K., Fusselman, M.J., Trask, D.D., McGuire, A.H. and McGuire, DJ. (1996) Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose. Radiology, 200, 243–247.PubMedGoogle Scholar
  20. Demers, L.M., Costa, L., Chinchilli, V.M., Gaydos, L., Curley, E. and Lipton, A. (1995) Biochemical markers of bone turnover in patients with metastatic bone disease. Clinical Chemistry, 41, 1489–1494.PubMedGoogle Scholar
  21. Galasko, C.S. (1986b) Skeletal metastases. Clinical Orthopaedics Related Research, 210, 18–30.Google Scholar
  22. Galasko, C.S.B. (1976) Mechanisms of bone destruction in the development of skeletal metastases. Nature, 263, 507–508.PubMedCrossRefGoogle Scholar
  23. Galasko, C.S.B. (1986a). Incidence and distribution of skeletal metastases. Cambridge, Butterworths Co.Google Scholar
  24. Gaze, M.N., Kelly, CG., Kerr, G.R., Cull, A., Cowie, V.J., Gregor, A., Howard, G.C.W. and Rodger, A. (1997) Pain relief and quality of life following radiotherapy for bone metastases: a randomised trial of two fraction schedules. Radiotherapy and Oncology, 45, 109–116.PubMedCrossRefGoogle Scholar
  25. Gilbert, R.W., Kim, J.H. and Posner, J.B. (1978) Epidural spinal cord compression from metastatic tumor: diagnosis and treatment. Annals of Neurology, 3, 40–51.PubMedCrossRefGoogle Scholar
  26. Glotzman, D. (1997) Mechanisms of the development of osteoblastic metastasis. Cancer [suppl], 80, 1581–1587.CrossRefGoogle Scholar
  27. Goldenberg, S.L., Bruchovsky, N., Rennie, P.S. and Coppin, C.M. (1988) The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma. Journal of Urology, 140, 1460–1465.PubMedGoogle Scholar
  28. Greenlee, R.T., Hill-Harmon, M.B., Murray, T. and Thun, M. (2001) Cancer statistics, 2001. CA: A Cancer Journal for Clinicians, 51, 15–36.CrossRefGoogle Scholar
  29. Haapiainen, R., Rannikko, S. and Alfthan, O. (1986) Comaprison of primary orchiectomy with oestrogen therapy in advanced prostatic cancer. British Journal of Urology, 58, 528–533.PubMedCrossRefGoogle Scholar
  30. Habermann, E.T., Sachs, R., Stern, R.E., Hirsh, D.M. and Anderson, W.J.J. (1982) The pathology and treatment of metastatic disease of the femur. Clinical Orthopaedics and Related Research, 169, 70–82.PubMedGoogle Scholar
  31. Hill, M.E., Richards, M.A., Gregory, W.M., Smith, P. and Rubens, R.D. (1993) Spinal cord compression in breast cancer: a review of 70 cases. British Journal of Cancer, 68, 969–973.PubMedCrossRefGoogle Scholar
  32. Holmberg, L., Bill-Axelson, A., Helgesen, F., Salo, J.O., Folmerz, P., Haggman, M. andersson, S.-O., Spangberg, A., Busch, C., Nordling, S., Palmgren, J., Adami, H.O., Johansson, J.E. and Norlen, B.J. (2002) A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. New England Journal of Medicine, 347, 781–789.PubMedCrossRefGoogle Scholar
  33. Hortobagyi, G.N., Theriault, R.L., Porter, L., Blayney, D., Lipton, A., Sinoff, C., Wheeler, H., Simeone, J.F., Seaman, J. and Knight, R.D. (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New England Journal of Medicine, 335, 1785–1791.PubMedCrossRefGoogle Scholar
  34. Ikeda, I., Miura, T. and Kondo, I. (1996) Pyridinium cross-links as urinary markers of bone metastasesnin patients with prostate cancer. British Journal of Urology, 77, 102–106.PubMedCrossRefGoogle Scholar
  35. Jacobs, S.C., Pikna, D. and Lawson, R.K. (1979) Prostatic osteoblastic factor. Investigational Urology, 17, 195–198.Google Scholar
  36. Jacobsson, H. Naslund, I. (1991) Reduced incidence of bone metastases in irradiated areas after external radiation therapy of prostatic carcinoma. International Journal of Radation Oncology Biological Physics, 20, 1297–1303.CrossRefGoogle Scholar
  37. Jilka, R.L., Hangoc, G., Girasole, G., Passeri, G., Williams, D. C, Abrams, J.S., Boyce, B., Broxmeyer, H. and Manolagas, S.C. (1992) Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science, 257, 88–91.PubMedCrossRefGoogle Scholar
  38. Johansson, J.-E., Holmberg, L., Johansson, S., Bergstrom, R. and Adami, H.-O. (1997) Fifteen-year survival in prostate cancer: a prospective, population-based study in Sweden. Journal of the American Medical Association, 277, 467–471.PubMedCrossRefGoogle Scholar
  39. Keller, E.T., Zhang, J., Cooper, C.R., Smith, P.C., McCauley, L.K., Pienta, K.J. and Taichman, R. S. (2001) Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer and Metastasis Reviews, 20, 333–349.PubMedCrossRefGoogle Scholar
  40. Ko, Y,-J., Small, E.J., Kabbinavar, F., Chachoua, A., Taneja, S., Reese, D., DePaoli, A., Hannah, A., Balk, S.P. and Bubley G. J. (2001) A multi-institutional phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormonerefractory prostate cancer. Clinical Cancer Research, 7, 800–805.PubMedGoogle Scholar
  41. Koeneman, K.S., Yeung, F. and Chung, L.W.K. (1999) Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate, 39, 246–261.PubMedCrossRefGoogle Scholar
  42. Koutsilieris, M., Rabbini, S.A., Bennett, H.P.J. and Goltzman, D. (1987) Characteristics of prostate-derived growth factors for cells of the osteoblast phenotype. Journal of Clinical Investigation, 80, 941–946.PubMedCrossRefGoogle Scholar
  43. Koutsilieris, M., Reyes-Moreno, C., Sourla, A., Dimitriadou, V. and Choki, I. (1997) Growth factors mediate glucocorticoid receptor function and dexamethasone-induced regression of osteoblastic lesions in hormone refractory prostate cancer. Anticancer Research, 17, 1461–1465.PubMedGoogle Scholar
  44. Kylmala, T., Tammela, T., Risteli, L., Risteli, J., Taube, T. and Elomaa, I. (1993) Evaluation of the effects of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. European Journal of Cancer, 29A, 821–825.PubMedCrossRefGoogle Scholar
  45. Lipton, A., Small, E., Saad, F., Gleason, D., Gordon, D., Smith, M., Rosen, L., Kowalski, M. O., Reitsma, D. and Seaman, J. (2002) The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Investigation, 20, 45–54.PubMedCrossRefGoogle Scholar
  46. Lowe, F.C. and Somers, W. J. (1987) The use of ketoconazole in the emergency management of disseminated intravascular coagulation due to metastatic prostate cancer. Journal of Urology, 137, 1000–1002.PubMedGoogle Scholar
  47. Maeda, H., Koizumi, M., Yoshimura, K., Yamauchi, T., Kawai, T. and Ogata, E. (1997) Correlation between bone metabolic markers and bone scan in prostate cancer. Journal of Urology, 157, 539–543.PubMedCrossRefGoogle Scholar
  48. Merrick, M.V., Ding, C.L., Chisholm, G.D. and Elton, R.A. (1985) Prognostic significance of alkaline and acid phosphatase and skeletal scintigraphy in carcinoma of the prostate. British Journal of Urology, 57, 715–720.PubMedCrossRefGoogle Scholar
  49. Mettlin, C.J., Murphy, G.P., Ho, R. and Menck, H. R. (1996) The national cancer data base report on longitudinal observations on prostate cancer. Cancer, 77, 2162–2166.PubMedCrossRefGoogle Scholar
  50. Nelson, J.B., Carducci, M.A., Padley, R.J., Janus, T., Humerickhouse, R. and Hippensteel, R. (2001). The endothelin-A receptor antagonist Atrasetan (ABT-627) reduces skeletal remodeling activity in men with advanced, hormone refractory prostate cancer. Proceedings of the American Society of Clinical Oncology, San Francisco, CA.Google Scholar
  51. Nelson, J.B., Hedican, S.P., George, D.J., Reddi, A.H., Piantadosi, S., Eisenberger, M.A. and Simons, J.W. (1995) Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nature Med, 1, 944–949.PubMedCrossRefGoogle Scholar
  52. Newling, D.W.W., Denis, L. and Vermeylen, K. (1993) Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Cancer, 72, 3793–3798.PubMedCrossRefGoogle Scholar
  53. Nielsen, O.S., Bentzen, S.M., Sandberg, E., Gadeberg, C.C. and Timothy, A.R. (1998) Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases. Radiotherapy and Oncology, 47, 233–240.PubMedCrossRefGoogle Scholar
  54. Oesterling, J.E., Brendler, C.B., Epstein, J.I., Kimball, A.W.J. and Walsh, P.C. (1987) Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate. Journal of Urology, 138, 92–98.PubMedGoogle Scholar
  55. Olumi, A.F., Grossfeld, G.D., Hayward, S.W., Carroll, P.R., Tlsty, T.D. and Cunha, G. R. (1999) Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Research, 59, 5002–5011.PubMedGoogle Scholar
  56. Osborne, C.K., Blumenstein, B., Crawford, E.D., Coltman, C. J., Smith, A.Y., Lambuth, B.W. and Chapman, R.A. (1990) Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study. Journal of Clinical Oncology, 8, 1675–1682.PubMedGoogle Scholar
  57. Percival, R.C., Urwin, G.H., Harris, S., Yates, A.J., Williams, J.L. and Beneton, M.E.A. (1987) Biochemical and histological prostate is associated with increased bone resorption. European Journal of Surgical Oncology, 13, 41–49.PubMedGoogle Scholar
  58. Pollen, J.J., Gerber, K., Ashburn, W.L. and Schmidt, J.D. (1981) Nuclear bone imaging in metastatic cancer of the prostate. Cancer, 47, 2585–2594.PubMedCrossRefGoogle Scholar
  59. Porter, A.T., McEwan, A.J.B., Powe, J.E., Reid, R., McGowan, D.G., Lukka, H., Sathyanarayana, J.R., Yakemchuk, V.N., Thomas, G.M., Erlich, L.E., Crook, J., Gulenchyn, K.Y., Hong, K.E., Wesolowski, C. and Yardley, J. (1993) Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Internationaljournal of Radiation Oncology Biological Physics, 25, 805–813.CrossRefGoogle Scholar
  60. Pound, C.R., Partin, A.W., Eisenberger, M.A., Chan, D.W., Pearson, J.D. and Walsh, P.C. (1999) Natural history of progression after PSA elevation following radical prostatectomy. Journal of the American Medical Association, 281, 1591–1597.PubMedCrossRefGoogle Scholar
  61. Quilty, P. M., Kirk, D., Bolger, J. J., Dearnaley, D. P., Lewington, V. J., Mason, M. D., Reed, N.S., Russell, J.M. and Yardley, J. (1994) A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiotherapy and Oncology, 31, 33–40.PubMedCrossRefGoogle Scholar
  62. Ransom, D.T., Dinapoli, R.P. and Richardson, R.L. (1990) Cranial nerve lesions due to base of the skull metastases in prostate carcinoma. Cancer, 65, 586–589.PubMedCrossRefGoogle Scholar
  63. Richardson, P.G., Barlogie, B., Berenson, J., Traynor, A., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, Z., Kuter, D., Limentani, S., Esseltine, D., Kauffman, M., Adams, J., Schenkein, D. and Anderson, K.C. (2002). Phase II study of the proteasome inhibitor PS-341 in multiple myeloma patients with relapsed/refractory disease. Proceedings of the American Society of Clinical Oncology, Orlando, FL.Google Scholar
  64. Robertson, C.N., Roberson, K.M., Padilla, G.M., O’Brien, E.T., Cook, M., Kim, C.S. and Fine, R.L. (1996) Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. Journal of the National Cancer Institute, 88, 908–917.PubMedCrossRefGoogle Scholar
  65. Rosenthal, D.I. (1997) Radiologic diagnosis of bone metastases. Cancer, 80, 1595–1607.PubMedCrossRefGoogle Scholar
  66. Saad, F., Gleason, D.M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J.L., Vinholes, J.J., Goad, J.A. and Chen, B. (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Journal of the National Cancer Institute, 94, 1458–1468.PubMedCrossRefGoogle Scholar
  67. Sartor, O., Cooper, M.R., Khleif, S.N. and Myers, C.E. (1994) Suramin decreases circulating levels of insulin-like growth factor-1. American Journal of Medicine, 96, 390.PubMedCrossRefGoogle Scholar
  68. Serafini, A.N., Houston, S.J., Resche, I., Quick, D.P., Grund, F.M., Ell, P.J., Bertrand, A., Ahmann, F.R., Orihuela, E., Reid, R.H., Lerski, R.A., Collier, B.D., McKillop, J.H., Purnell, G.L., Pecking, A.P., Thomas, F.D. and Harrison, K.A. (1998) Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. Journal of Clinical Oncology, 16, 1574–1581.PubMedGoogle Scholar
  69. Shariat, S.F., Lamb, DJ., Kattan, M.W., Nguyen, C., Kim, J., Beck, J., Wheeler, T.M. and Slawin, K.M. (2002) Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and-3 with prostate cancer invasion, progression, and metastasis. Journal of Clinical Oncology, 20, 833–841.PubMedCrossRefGoogle Scholar
  70. Shreve, P.D., Grossman, H.B., Gross, M.D. and Wahl, R.L. (1996) Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18] fluoro-D-glucose. Radiology, 199, 751–756.PubMedGoogle Scholar
  71. Simpson, E., Harrod, J. and Eilan, G. e. a. (1985) Identification of a messenger ribonucleic acid fraction in human prostatic cancer cells coding for a novel osteoblast-stimulating factor. Endocrinology, 117, 1615–1620.PubMedCrossRefGoogle Scholar
  72. Small, E.J., Meyer, M. Marshall, M.E., et al. (2000) Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. Journal of Clinical Oncology, 18, 1440–1450.PubMedGoogle Scholar
  73. Smith, D.C., Tucker, J.A. and Trump, D.L. (1992) Hypercalcemia and neuroendocrine carcinoma of the prostate: a report of three cases and a review of the literature. Journal of Clinical Oncology, 10, 499–505.PubMedGoogle Scholar
  74. Soloway, M.S., Hardeman, S.W., Hickey, D., Raymond, J., Todd, B., Soloway, S. and Moinuddin, M. (1988) Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer, 61, 195–202.PubMedCrossRefGoogle Scholar
  75. Storlie, J.A., Buckner, J.C., Wiseman, G.A., Burch, P.A., Hartmann, L.C. and Richardson, R.L. (1995) Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer, 76, 96–100.PubMedCrossRefGoogle Scholar
  76. Taichman, R.S., Cooper, C., Keller, E.T., Pienta, K.J., Taichman, N.S. and McCauley, L.S. (2002) Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Research, 62, 1832–1837.PubMedGoogle Scholar
  77. Takeuchi, S.-i., Arai, K., Saitoh, H., Yoshida, K.-i. and Miura, M. (1996) Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer. Journal of Urology, 156, 1691–1695.PubMedCrossRefGoogle Scholar
  78. Taube, T., Kylmala, T., Lamberg-Allardt, C., Tammela, T.L.J. and Elomma, I. (1994) The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a double-blind randomised placebo-controlled study. European Journal of Cancer, 30A, 751–758.PubMedCrossRefGoogle Scholar
  79. Thalmann, G.N., Anezinis, P.E., Chang, S., Zhau, H.E., Kim, E., Hopwood, V.L., Pathak, S., von Eschenbach, A.C. and Chung, L.W.K. (1994) Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Research, 54,2577–2581.PubMedGoogle Scholar
  80. Tong, D., Gillick, L. and Hendrickson, F.R. (1982) The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group. Cancer, 50, 893–899.PubMedCrossRefGoogle Scholar
  81. Townsend, M.F., Sanders, W.H., Northway, R.O. and Graham, S.D.J. (1997) Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer, 79, 545–550.PubMedCrossRefGoogle Scholar
  82. Trachtenberg, J., Halpern, N. and Pont, A. (1983) Ketoconazole: a novel and rapid treatment for advanced prostate cancer. Journal of Urology, 130, 152–153.PubMedGoogle Scholar
  83. Tu, S.-M., Millikan, R.E., Mengistu, B., Delpassand, E.S., Amato, R.J., Pagliaro, L.C., Daliani, D., Papandreou, C.N., Smith, T.L., Kim, J., Podoloff, D.A. and Logothetis, C.J. (2001) Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized phase II trial. Lancet, 357, 336–341.PubMedCrossRefGoogle Scholar
  84. Tu, S.-M., Pagliaro, L.C., Banks, M.E., Amato, R.J., Millikan, R.E., Bugazia, N.A., Madden, T., Newman, R.A. and Logothetis, C.J. (1998) Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer. Clinical Cancer Research, 4, 1193–1201.PubMedGoogle Scholar
  85. Vinholes, J.J.F., Purohit, O.P., Abbey, M.E. and Coleman, R.E. (1997) Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Annals of Oncology, 8, 1243–1250.PubMedCrossRefGoogle Scholar
  86. Wood, D.P. and Banerjee, M. (1997) Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. Journal of Clinical Oncology, 15, 3451–3457.PubMedGoogle Scholar
  87. Xie, S.P., Pirianov, G. and Colston, K.W. (1999) Vitamin D analogues suppress IGF-1 signalling and promote apoptosis in breast cancer cells. European Journal of Cancer, 35, 1717–1723.PubMedCrossRefGoogle Scholar
  88. Zagars, G.K., Pollack, A. and von Eschenbach, A.C. (1995) Prostate cancer and radiation therapy-message conveyed by serum prostate-specific antigen. International Journal of Radiation Oncology, Biology, Physics, 33, 23–35.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • Shi-Ming Tu
    • 1
  • Sue-Hwa Lin
    • 1
    • 2
  1. 1.Department of Genitourinary Medical OncologyThe University of Texas, M.D. Anderson Cancer CenterHoustonUSA
  2. 2.Molecular PathologyThe University of Texas, M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations